1875 — BioDlink International Share News
0.000.00%
Last trade - 00:00- HK$2.59bn
- HK$2.70bn
- CNY747.65m
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29
Brief: Biodlink International Says Fu, Shan Re-Designated From To An Executive Director
Brief: TOT Biopharm International Posts FY Net Income Of RMB34.757 Mln
Brief: TOT BIOPHARM International Posts H1 Revenue RMB520.603 Million
Brief: TOT Biopharm International Co Posts FY Loss Attributable RMB49.9 Mln VS Loss RMB261.2 Mln
Brief: TOT Biopharm International Announces Termination Of Phase III Development Of TAA013
Brief: TOT Biopharm International Says Revenue Increased To RMB442,178 Thousand For Year
Brief: Tot Biopharm International Says Yeh-Huang, Chun-Ying Re-Designated To Non-Executive Director
Brief: Tot Biopharm International Says 9M Revenue RMB305.8 Mln
Brief: Tot Biopharm International Says Unit Received Gmp Compliance Inspection Report
Brief: Tot Biopharm International Records HY Revenue Rmb182.0 Mln
Brief: Tot Biopharm International Conditionally Agreed To Allot & Issue 33.8 Mln Subscription Shares
Brief: Tot Biopharm International-Unit Received Notice Of Approval Of Its Supplemental Application For Bevacizumab Injection Issued By NMPA
Brief: Tot Biopharm International Says Unit Received Approval Of Its Supplemental Application For New Indications Of Bevacizumab Injection
Brief: Tot Biopharm International's Unit Entered Into Commercialization License With Kexing Biopharm
Brief: Tot Biopharm International Says Unit Entered Into Construction Agreement With Shanghai Baoye